Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PSMC1P4 is a human pseudogene that corresponds to the proteasome 26S subunit, ATPase 1 (PSMC1) gene[1]. Unlike the protein-coding PSMC1 gene, PSMC1P4 does not produce a functional protein product and is not involved in encoding an active proteasome subunit. Pseudogenes are typically nonfunctional remnants of gene duplication or retrotransposition events. Therefore, PSMC1P4 is not considered a therapeutic target, does not have biological functions, and has no known disease associations, drug interactions, mechanisms of action, known biomarkers, or safety concerns[1]. Key points: - PSMC1P4 is a pseudogene, not an active gene or protein[1]. - It is not a drug target—therapeutic interventions do not act on this pseudogene. - No functional, mechanistic, or biomarker relevance is reported. - The confusion may arise because the active gene, PSMC1, does encode an essential subunit of the 26S proteasome—a validated therapeutic target in cancer and other diseases[2][5][7]. However, PSMC1P4 itself does not have these properties. If you require information on the active subunit/target (PSMC1), a separate entry should be used.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome 26S subunit, ATPase 1 pseudogene 4 (PSMC1P4).